CancerDetect™ is a multi-cancer early detection method that analyzes genetic material released into the bloodstream by tumors or other cells in the body. It can detect genetic alterations associated with various diseases, including cancer.
CancerDetect™ can detect genetic alterations, including mutations, copy number variations (CNV), and rearrangements, in specific genes or genomic regions. It is commonly used for cancer diagnosis, monitoring treatment response, and detecting minimal residual disease.
CancerDetect™ involves collecting a blood sample from a patient. The blood sample is then processed to isolate circulating genetic material, which will then be analyzed through next-generation sequencing (NGS) to identify specific genetic alterations.
Traditional biopsies involve the removal of tissue samples for analysis, while CancerDetect™ uses a blood sample to analyze circulating genetic material. Liquid biopsy is relatively less invasive, and provides a comprehensive view of tumor genetics.
CancerDetect™ has shown a promising accuracy in detecting genetic alterations in various diseases. While it may not replace traditional tissue biopsy in all cases, it offers a minimally invasive alternative and can provide valuable information about tumor genetics.
While CancerDetect™ offers several advantages, it may not completely replace traditional biopsies in all cases. It complements the traditional biopsies. Traditional biopsies provide detailed histological information and allow for precise tumor characterization, which may still be necessary for certain clinical decisions.
CancerDetect™ and imaging scans serve different purposes in cancer monitoring. While liquid biopsy can provide genetic (molecular) information about the tumor, imaging scans such as CT, MRI, or PET scans are essential for assessing tumor size, location, and metastasis. Both approaches are often used together to provide a comprehensive picture of the disease.
CancerDetect™ offers several advantages, including its non-invasive nature, the ability to track disease progression over time, and the potential for early detection of cancer recurrence. It also allows for the analysis of tumor heterogeneity and can be performed more frequently than tissue biopsies.
Yes, CancerDetect™ has the potential to detect genetic alterations associated with cancer at an early stage. By analyzing circulating tumor DNA, it may help identify cancer before it becomes clinically apparent, improving the chances of successful treatment.
CancerDetect™ is considered a low-risk procedure with minimal side effects. Since it involves a blood draw, there may be slight discomfort or bruising at the site of sample collection. Serious complications are rare.
The turnaround time for CancerDetect™ is between 7 to 10 working days.
Yes, CancerDetect™ has great potential for personalized medicine. By analyzing the genetic profile of tumors, it can provide insights into specific mutations or alterations that can guide treatment decisions and monitor treatment response over time.
CancerDetect™ can detect up to 85 types of cancers, including lung, breast, colorectal, prostate, and pancreatic cancer. It can also be used for hematological malignancies such as leukemia and lymphoma.
CancerDetect™ can be informative across different stages of cancer. It can aid in early detection, provide prognostic information, guide treatment selection, monitor treatment response, and detect minimal residual disease. However, its sensitivity and specificity may vary depending on the specific cancer type and stage.
CancerDetect™ can detect various types of genetic alterations, including point mutations, insertions/deletions, gene fusions, and copy number variations. However, the detection of certain alterations may depend on the sensitivity and specificity of the testing method employed.
Yes, CancerDetect™ can identify genetic alterations associated with treatment resistance. By monitoring the presence of specific mutations during treatment, it can help guide adjustments in therapy to overcome resistance and improve patient outcomes.
Yes, CancerDetect™ is valuable for the early detection of cancer recurrence in survivors. By monitoring for the presence of specific genetic alterations associated with the tumor, it can provide early warning signs of recurrence, enabling timely intervention and treatment.
CancerDetect™ does not have specific age restrictions and can be performed on patients of various ages. The suitability of testing depends more on the specific clinical context, the availability of targeted therapies, and the presence of detectable genetic alterations.
While CancerDetect™ shows promise, it is primarily used in the context of diagnosing and monitoring diseases like cancer. However, its application is suitable for healthy individuals as a general genetic screening tool.
The frequency of CancerDetect™ depends on the specific clinical situation and the treatment plan. It can be performed at different time points, such as initial diagnosis, during treatment, and during follow-up, to monitor disease progression and treatment response. The frequency is determined by the healthcare provider based on individual patient needs.
In most cases, fasting is not required before undergoing liquid biopsy genetic testing. It is a simple blood test that can be done at any time, regardless of food intake.
CancerDetect™ can help identify the tissue of origin in some cases of metastatic cancer. By analyzing the genetic alterations, it can provide clues about the primary tumor site. However, it may not always definitively determine the primary site, and additional imaging and clinical information are usually required for accurate diagnosis.
CancerDetect™ is particularly valuable for monitoring treatment response in targeted therapies. By analyzing specific genetic alterations associated with the targeted therapy, it can provide insights into treatment effectiveness and the emergence of resistance mutations.
There are no specific pre-test requirements for liquid biopsy genetic testing. However, it is essential to follow any instructions provided by the healthcare provider or the testing laboratory regarding sample collection and handling.
CancerDetect™ is primarily focused on detecting genetic alterations associated with diseases like cancer. It is not commonly used for detecting inherited genetic conditions, as those typically require different testing methods such as targeted genetic sequencing. You may refer to SuperDNA Ultimate test for detection of hereditary genetic conditions.
Several factors can potentially affect the accuracy of liquid biopsy genetic testing, including the sensitivity and specificity of the testing method used, the amount of circulating tumor DNA present, tumor heterogeneity, and technical limitations of the assay. Quality control measures and validation studies are performed to optimize accuracy.